A series of cardiometabolic-related news items has been observed from Novo Nordisk, Dexcom, Amgen, and Lilly. Below, FENIX provides highlights and insights for the respective news items.
Three cardiometabolic-related news items have been observed: Lilly hosted its Q1 ’25 earnings call (press release; slides); Wegovy received preferred GLP-1RA status on CVS’s formulary (view press release); and Madrigal Pharmaceuticals hosted its Q1 ’25 earnings call (press release; slides). Below, FENIX provides highlights and insights from the respective news items.
A series of cardiometabolic-related news items has been observed from WeightWatchers, Creyon Bio, Tandem Diabetes Care, and Lilly. Below, FENIX provides highlights and insights for the respective news items.
A series of cardiometabolic-related news items has been observed from Lilly, Ascletis Pharma, and Zealand Pharma. Below, FENIX provides highlights and insights for the respective news items.
Lilly announced topline results from its first Ph3 pivotal orforglipron (oral QD GLP-1RA) trial (ACHIEVE-1; view CT.gov record) demonstrating -1.5% reduction in A1C and -7.9% weight loss at the highest dose (36mg) at Week 40. For context, ACHIEVE-1 (n=559) evaluated the safety and efficacy of orforglipron vs placebo in adults with T2DM and inadequate glycemic control with diet and exercise alone. Lilly’s stock increased ~15% following the announcement. Below, FENIX provides highlights and insights from the ACHIEVE-1 trial, including readthrough to other obesity assets in development.
A series of cardiometabolic-related news items has been observed from Lilly, Nurx, and Biophytis. Below, FENIX provides highlights and insights for the respective news items.
Two cardiometabolic news items have been observed: Novo Nordisk announced a $1.09B investment to boost manufacturing capacity in Brazil (view press release); and Teladoc Health announced the launch of a new cardiometabolic health program (view press release). Below, FENIX provides highlights and insights for the respective news items.
A series of cardiometabolic new items has been observed from Lilly, CMS, Ypsomed/Sidekick Health, and Breakthrough Prize Foundation. Below, FENIX provides highlights and insights for the respective news items.
Two cardiometabolic news items have been observed: Lilly has sued Strive and Empower over compounded tirzepatide (view article); and Inventiva completed patient enrollment in its Ph3 NATiV3 study in MASH (view press release). Below, FENIX provides highlights and insights for the respective news items.
A series of cardiometabolic-related news items has been observed from Novo Nordisk, Lilly, AstraZeneca, Vertex Pharmaceuticals, Palatin Technologies, Noom, and SAB BIO. Additionally, FENIX will cover Biomea Fusion’s FY 2024 earnings in tomorrow’s blast. Below, FENIX provides highlights and insights for the respective news items.